Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224224 | 0.94 | SMN1; SMN2 (0.39) | SMN1; SMN2POLBTHRBTP53MAPT | |
| SCHEMBL4228394 | 0.86 | PPARG (0.39) | MEN1KMT2AAKR1C3PPARGPPARA | |
| SCHEMBL333812 | 0.86 | ALOX5 (0.43) | SMN1; SMN2POLBALOX5THRBTP53 | |
| SCHEMBL335343 | 0.86 | THRB (0.44) | SMN1; SMN2POLBALOX5THRBTP53 | |
| Water SCHEMBL4228628 | 0.85 | PPARG (0.39) | MEN1KMT2AAKR1C3PPARGPPARA | |
| SCHEMBL334124 | 0.79 | ALOX5 (0.43) | SMN1; SMN2POLBALOX5THRBTP53 | |
| SCHEMBL4221842 | 0.79 | PTGES (0.44) | MEN1KMT2APPARGPPARA | |
| SCHEMBL333779 | 0.79 | PPARG (0.47) | SMN1; SMN2POLBTHRBTP53MAPT | |
| SCHEMBL4223256 | 0.79 | PTGES (0.46) | SMN1; SMN2POLBTHRBTP53MAPT | |
| SCHEMBL333940 | 0.79 | PTGES (0.44) | SMN1; SMN2POLBTHRBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | SMN1; SMN2 3779/4885POLB 4597/4885ALOX5 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.